These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
4. Epithelial Antimicrobial Peptide/Protein and Cytokine Expression Profiles Obtained from Nasopharyngeal Swabs of SARS-CoV-2-Infected and Non-Infected Subjects. Gambichler T; Goesmann S; Skrygan M; Susok L; Schütte C; Hamdani N; Schmidt W Viruses; 2024 Sep; 16(9):. PubMed ID: 39339947 [TBL] [Abstract][Full Text] [Related]
5. Comparison by Age of the Local Interferon Response to SARS-CoV-2 Suggests a Role for IFN-ε and -ω. Pierangeli A; Gentile M; Oliveto G; Frasca F; Sorrentino L; Matera L; Nenna R; Viscido A; Fracella M; Petrarca L; D'Ettorre G; Ceccarelli G; Midulla F; Antonelli G; Scagnolari C Front Immunol; 2022; 13():873232. PubMed ID: 35903094 [TBL] [Abstract][Full Text] [Related]
6. Human Nasal and Lung Tissues Infected Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170 [TBL] [Abstract][Full Text] [Related]
7. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Hatton CF; Botting RA; Dueñas ME; Haq IJ; Verdon B; Thompson BJ; Spegarova JS; Gothe F; Stephenson E; Gardner AI; Murphy S; Scott J; Garnett JP; Carrie S; Powell J; Khan CMA; Huang L; Hussain R; Coxhead J; Davey T; Simpson AJ; Haniffa M; Hambleton S; Brodlie M; Ward C; Trost M; Reynolds G; Duncan CJA Nat Commun; 2021 Dec; 12(1):7092. PubMed ID: 34876592 [TBL] [Abstract][Full Text] [Related]
8. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094 [TBL] [Abstract][Full Text] [Related]
9. Type I and III interferon responses in SARS-CoV-2 infection. Kim YM; Shin EC Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323 [TBL] [Abstract][Full Text] [Related]
10. Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Suppresses Type I and Type III Interferon Induction by Targeting RIG-I Signaling. Chang CY; Liu HM; Chang MF; Chang SC J Virol; 2020 Jun; 94(13):. PubMed ID: 32295922 [TBL] [Abstract][Full Text] [Related]
11. IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN. Solstad AD; Denz PJ; Kenney AD; Mahfooz NS; Speaks S; Gong Q; Robinson RT; Long ME; Forero A; Yount JS; Hemann EA JCI Insight; 2024 May; 9(13):. PubMed ID: 38973611 [TBL] [Abstract][Full Text] [Related]